BioPharmSignal logoBioPharmSignal

Company Profile

Cullinan Therapeutics, Inc. Stock Price, News & Catalysts

Ticker:
CGEM
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

19.60 USD (-0.15%)

Close

Last updated: August 12, 2026

943M USD

Market cap

Why the stock is moving

As of Aug 12, 2026, CGEM was little changed and closed at $19.60. No new same-company headline was identified in the current news window.

Company overview

Autoimmune and Oncology Therapeutics

Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer.

CLN-978

CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose evaluation.

Zipalertinib

Zipalertinib is an oral EGFR inhibitor under FDA review for previously treated EGFR exon 20 insertion-positive non-small cell lung cancer.

Velinotamig

Velinotamig is a BCMA-directed T-cell engager in clinical development for multiple myeloma.

Future catalysts

  • Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.
  • Multi-dose rheumatoid-arthritis data for CLN-978 in the third quarter of 2026.
  • Additional clinical data for velinotamig during 2026.
  • PDUFA target action date for zipalertinib on February 27, 2027.

Recent news

  1. 01

    Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

  2. 02

    Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

  3. 03

    Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

  4. 04

    Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

  5. 05

    Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

KPTI

Karyopharm Therapeutics

IMRX

Immuneering

IOBT

IO Biotech

DAWN

Day One Biopharmaceuticals

ITOS

iTeos Therapeutics

DCPH

Deciphera Pharmaceuticals

BYSI

BeyondSpring, Inc.

SNDX

Syndax Pharmaceuticals

Frequently Asked Questions

What is the current stock price of Cullinan Therapeutics, Inc. (CGEM)?

Cullinan Therapeutics, Inc. (CGEM) most recently closed at 19.60 USD, a -0.15% move versus the previous session.

What is the market cap of Cullinan Therapeutics, Inc. (CGEM)?

Cullinan Therapeutics, Inc. currently has a market capitalization of 943M USD on BioPharmSignal.

What does Cullinan Therapeutics, Inc. do?

Autoimmune and Oncology Therapeutics Cullinan Therapeutics develops targeted therapies and immune-cell engagers across autoimmune disease and cancer. CLN-978 CLN-978 is a compact CD19-directed T-cell engager designed to deplete B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis, including multi-dose...

On which exchange is CGEM stock listed?

Cullinan Therapeutics, Inc. (CGEM) is associated with NASDAQ, United States, Biopharma.

What is CLN-978?

Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.

Which conditions is Cullinan Therapeutics, Inc. targeting with CLN-978?

Cullinan Therapeutics, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

How does Cullinan Therapeutics, Inc. describe recent progress with CLN-978?

Initial CLN-978 data in lupus and rheumatoid arthritis at EULAR 2026.

What is zipalertinib?

Zipalertinib Zipalertinib is an oral EGFR inhibitor under FDA review for previously treated EGFR exon 20 insertion-positive non-small cell lung cancer.